| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RAB22A |
| Uniprot No | Q9UL26 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-194aa |
| 氨基酸序列 | MALRELKVCL LGDTGVGKSS IVWRFVEDSF DPNINPTIGA SFMTKTVQYQ NELHKFLIWD TAGQERFRAL APMYYRGSAA AIIVYDITKE ETFSTLKNWV KELRQHGPPN IVVAIAGNKC DLIDVREVME RDAKDYADSI HAIFVETSAK NAININELFI EISRRIPSTD ANLPSGGKGF KLRRQPSEPK RSCC |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与RAB22A重组蛋白相关的研究文献概述(虚拟示例，实际文献请通过学术数据库检索)：
1. **《RAB22A mediates epithelial-mesenchymal transition in cancer metastasis》**
- 作者：Zhang Y. et al.
- 摘要：研究利用RAB22A重组蛋白体外验证其与EGFR的相互作用，发现其通过激活MAPK信号通路促进肿瘤细胞侵袭转移。
2. **《RAB22A regulates autophagosome-lysosome fusion》**
- 作者：Deng Q. et al.
- 摘要：通过重组RAB22A蛋白的GTPase结构域突变体实验，揭示其通过竞争性结合HOPS复合体抑制自噬体成熟，影响细胞代谢稳态。
3. **《Structural basis of RAB22A interaction with the retromer complex》**
- 作者：Liu X. et al.
- 摘要：利用重组RAB22A蛋白进行晶体结构解析，阐明其与VPS35蛋白的互作界面，为靶向囊泡运输的药物开发提供依据。
4. **《RAB22A overexpression confers chemoresistance in ovarian cancer》**
- 作者：Wang L. et al.
- 摘要：通过重组RAB22A蛋白处理细胞模型，证实其通过调控ABCB1转运蛋白膜定位增强癌细胞对紫杉醇耐药性。
注：以上为模拟摘要，实际文献请通过PubMed/Google Scholar检索关键词"RAB22A recombinant protein"或结合具体研究领域筛选。
**Background of RAB22A Recombinant Protein**
RAB22A, a member of the Rab GTPase family, plays a critical role in regulating intracellular vesicular trafficking and membrane dynamics. This small GTPase cycles between an active GTP-bound state and an inactive GDP-bound state, acting as a molecular switch to control endosomal sorting, endocytosis, and recycling of cell surface receptors. RAB22A is particularly associated with early endosomes and has been implicated in modulating endosome-lysosome pathways, autophagy, and the formation of tubular vesicles.
The recombinant RAB22A protein is engineered through molecular cloning and expression systems (e.g., *E. coli* or mammalian cells) to produce a purified, functional form for research applications. It retains the biochemical properties of native RAB22A, enabling studies on its interaction with effector proteins, GTP/GDP binding kinetics, and regulatory mechanisms. Recombinant RAB22A is widely used to investigate its role in cellular processes such as cancer progression, where dysregulated RAB22A expression correlates with tumor invasion, metastasis, and drug resistance. For example, RAB22A promotes epithelial-mesenchymal transition (EMT) in cancers by enhancing recycling of pro-invasive receptors (e.g., integrins) or activating oncogenic signaling pathways like MAPK/ERK.
Additionally, RAB22A has emerged as a potential therapeutic target. Studies highlight its involvement in pathogen invasion (e.g., *Salmonella* hijacking host endosomes) and immune evasion mechanisms. The recombinant protein serves as a tool for screening inhibitors or designing targeted therapies. Despite progress, further research is needed to elucidate its tissue-specific functions and post-translational modifications. Overall, RAB22A recombinant protein provides a versatile platform for dissecting vesicular trafficking mechanisms and their implications in disease.
(Word count: 249)
×
